Survivor demographic and treatment characteristics
| . | Participants . | . | |
|---|---|---|---|
| N = 102 . | |||
| Demographics | N | % | |
| Gender | |||
| Female | 56 | 54.9 | |
| Male | 46 | 45.1 | |
| Race | |||
| White | 96 | 94.1 | |
| Other | 6 | 5.9 | |
| Highest grade | |||
| College graduate | 32 | 31.4 | |
| Noncollege graduate | 70 | 68.6 | |
| Current employment | |||
| Full time | 62 | 60.8 | |
| Part time or unemployed | 38 | 37.3 | |
| Mean | SD | Min-Max | |
| Current age (y) | 38.4 | 6.2 | 27-55 |
| Treatment factors | |||
| IT MTX (mL) | 103.6 | 88.5 | 0-496 |
| IV MTX (g/m2) | 2.22 | 2.90 | 0-21.8 |
| Age (y) | |||
| At diagnosis | 5.0 | 3.2 | 0.8-15.3 |
| At initial testing | 11.0 | 3.8 | 4.3-23.1 |
| At follow-up testing | 38.5 | 6.2 | 26.6-54.7 |
| End of therapy to initial testing (y) | 3.4 | 2.3 | 1.0-9.3 |
| Diagnosis to follow-up testing (y) | 33.5 | 5.7 | 18.8-46.4 |
| Initial to follow-up testing (y) | 27.6 | 5.6 | 14.0-38.4 |
| CRT dose (Gy) | N | % | |
| 18 | 34 | 33.3 | |
| 24 | 68 | 66.7 | |
| Neurocognitive assessment | Mean | SD | |
| Nonparticipants (n = 36) | |||
| IQ at initial testing | |||
| Verbal | 92.7 | 14.6 | |
| Performance | 93.6 | 17.0 | |
| Full Scale | 92.4 | 15.4 | |
| Participants (n = 102) | |||
| IQ at initial testing | |||
| Verbal | 97.4 | 15.4 | |
| Performance | 95.3 | 16.5 | |
| Full Scale | 96.0 | 15.9 | |
| IQ at follow-up testing | |||
| Verbal | 87.1 | 17.1 | |
| Performance | 95.7 | 16.8 | |
| Full Scale | 91.3 | 15.5 | |
| Academic | |||
| Reading | 91.3 | 9.8 | |
| Mathematics | 85.8 | 17.48 | |
| Attention: sustained | 89.7 | 16.99 | |
| Processing speed | 89.5 | 27.45 | |
| Memory | |||
| Total recall | 92.7 | 18.14 | |
| Long-term | 92.4 | 18.94 | |
| Executive function | |||
| Fluency | 89.3 | 16.07 | |
| Flexibility | 77.6 | 32.01 | |
| . | Participants . | . | |
|---|---|---|---|
| N = 102 . | |||
| Demographics | N | % | |
| Gender | |||
| Female | 56 | 54.9 | |
| Male | 46 | 45.1 | |
| Race | |||
| White | 96 | 94.1 | |
| Other | 6 | 5.9 | |
| Highest grade | |||
| College graduate | 32 | 31.4 | |
| Noncollege graduate | 70 | 68.6 | |
| Current employment | |||
| Full time | 62 | 60.8 | |
| Part time or unemployed | 38 | 37.3 | |
| Mean | SD | Min-Max | |
| Current age (y) | 38.4 | 6.2 | 27-55 |
| Treatment factors | |||
| IT MTX (mL) | 103.6 | 88.5 | 0-496 |
| IV MTX (g/m2) | 2.22 | 2.90 | 0-21.8 |
| Age (y) | |||
| At diagnosis | 5.0 | 3.2 | 0.8-15.3 |
| At initial testing | 11.0 | 3.8 | 4.3-23.1 |
| At follow-up testing | 38.5 | 6.2 | 26.6-54.7 |
| End of therapy to initial testing (y) | 3.4 | 2.3 | 1.0-9.3 |
| Diagnosis to follow-up testing (y) | 33.5 | 5.7 | 18.8-46.4 |
| Initial to follow-up testing (y) | 27.6 | 5.6 | 14.0-38.4 |
| CRT dose (Gy) | N | % | |
| 18 | 34 | 33.3 | |
| 24 | 68 | 66.7 | |
| Neurocognitive assessment | Mean | SD | |
| Nonparticipants (n = 36) | |||
| IQ at initial testing | |||
| Verbal | 92.7 | 14.6 | |
| Performance | 93.6 | 17.0 | |
| Full Scale | 92.4 | 15.4 | |
| Participants (n = 102) | |||
| IQ at initial testing | |||
| Verbal | 97.4 | 15.4 | |
| Performance | 95.3 | 16.5 | |
| Full Scale | 96.0 | 15.9 | |
| IQ at follow-up testing | |||
| Verbal | 87.1 | 17.1 | |
| Performance | 95.7 | 16.8 | |
| Full Scale | 91.3 | 15.5 | |
| Academic | |||
| Reading | 91.3 | 9.8 | |
| Mathematics | 85.8 | 17.48 | |
| Attention: sustained | 89.7 | 16.99 | |
| Processing speed | 89.5 | 27.45 | |
| Memory | |||
| Total recall | 92.7 | 18.14 | |
| Long-term | 92.4 | 18.94 | |
| Executive function | |||
| Fluency | 89.3 | 16.07 | |
| Flexibility | 77.6 | 32.01 | |
Cumulative doses listed for intrathecal (IT) and intravenous (IV) methotrexate (MTX). Initial testing denotes first testing ≥1 year and ≤10 years after CRT. Follow-up testing denotes current testing. All neurocognitive assessment scores presented in age-adjusted standard scores with an expected mean of 100 and and SD of 15. Participants did not differ from nonparticipants in initial Verbal IQ (P = .12), Performance IQ (P = .60), or Full Scale IQ (P = .24).
IT, intrathecal; IV, intravenous; Min-Max, minimum-maximum; MTX, methotrexate.